BioMarin recruits Vertex's translational chief to head up clinical trial ops
After spending the last 4 years pushing translational research at the deep science-focused Vertex, Harold Bernstein is making the leap into the clinical world, planting both feet in drug development as BioMarin’s new SVP and chief medical officer.
Bernstein’s new role puts him in charge of clinical development at the San Francisco-based biotech where things haven’t always gone smoothly. Most notably, BioMarin’s often-touted hemophilia A gene therapy has displayed a tendency to waning efficacy, raising doubts that prompted the FDA to impose a lengthy delay on the company before any marketing decision.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,300+ biopharma pros reading Endpoints daily — and it's free.